Purpose: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a prevalent urological condition in young men, significantly affecting quality of life due to persistent discomfort and neuropsychological symptoms. Despite its high prevalence, the etiology of CP/CPPS remains poorly understood. This study investigated urinary microbiota differences between CP/CPPS patients and healthy controls to identify microbial contributors, antibiotic resistance genes (ARGs), and virulence factors of dominant bacteria, as well as to explore potential therapeutic targets. Methods: Urine samples were collected from 58 CP/CPPS patients and 25 controls. Symptom severity was assessed by a specialist urologist using the NIH Chronic Prostatitis Symptom Index and UPOINT classification. Bacterial-specific 16 S rRNA sequencing was performed using nanopore technology, with bioinformatics analyses conducted via ONT guppy 5.0.11, NCBI and SLV 16 S bacterial taxonomic databases, UPGMA hierarchical clustering, and the Bacterial and Viral Bioinformatics Resource Center (BV-BRC). Pairwise comparisons were analyzed using the Mann-Whitney U test. Results: Distinct microbial diversity patterns were observed between patients and controls. Bacillus species were significantly enriched in CP/CPPS patients, while Enterococcus species predominated in controls. Younger patients exhibited unique microbiome profiles compared to older groups. Bioinformatics analyses identified ARGs and virulence factors associated with Bacillus species, implicating them in localized inflammation. Antibiotics like pleuromutilin or vancomycin were identified as potential therapeutic options, though experimental validation was beyond the study’s scope. Conclusion: These findings highlight microbial imbalances and provide a foundation for microbiome-targeted therapeutic strategies for CP/CPPS management in the future. Additionally, the identification of bacterial virulence factors and ARG provides insights into the potential mechanisms driving persistent symptoms. Future research with larger cohorts and experimental validation of the suggested therapeutic options may contribute to more effective treatment for CP/CPPS.
The genus Aeromonas, specifically the species A. hydrophila (Sawyer, 1986) and A. sobria (McCovan and Steinberg, 1995), has been identified for the first time in the Western Black Sea [BK] and Manyas Lake [M] through species identification using the API 20E test system and metagenomic analysis. This study presents a metagenomic analysis of bacterial isolates sourced from various locations of Küçükçekmece Lake, Manyas Lake, and the Western Black Sea Region. The research was conducted at the Istanbul University Department of Biology, Department of Basic and Industrial Microbiology (TEMA) Laboratory. The isolate was subjected to phenotypic analysis using fundamental biochemical methods, which included conventional biochemical tests and two commercially available systems, Vitek (GNI+) and API (20E). Genotypically, it was compared through multi-array alignment based on the 16S bacterial rRNA gene. By applying the polymerase chain reaction (PCR) and sequencing the 16S ribosomal RNA (rRNA) gene, the isolated bacterial genomes were amplified and sequenced. Following repeated sequence alignment and position correction, the resultant sequences were compared to known 16S rRNA gene sequences in the SILVA (Version 99) database.
This review highlights the emerging role of the immune checkpoint receptor T cell immunoglobulin and mucin-domain containing-3 (TIM-3) as a crucial modulator in the prostate's microbiome-immune axis, with significant implications for prostate-related diseases such as prostatitis, benign prostatic hyperplasia (BPH), and prostate cancer. These conditions reflect the prostate's susceptibility to immune dysregulation, which is influenced by microbial communities and their metabolites. TIM-3, already known for its role in immune regulation in cancer and chronic infections, is now recognized for its potential to shape immune responses within the prostate by modulating regulatory T cells (Tregs) and influencing inflammation and tolerance. Microbial metabolites, such as short-chain fatty acids (SCFAs), and pro-inflammatory bacterial components like lipoteichoic acid can alter TIM-3 expression, contributing to immune imbalance. Therapeutic strategies targeting TIM-3 aim to restore immune equilibrium, while complementary microbiome-focused approaches, such as probiotics, dietary interventions, pH modulation, and enhancement of epithelial antimicrobial peptides, may further prevent microbial overgrowth and inflammation. Drawing parallels with therapies for inflammatory bowel disease and other immune-related conditions, the integration of TIM-3 blockade with microbiota modulation presents a promising avenue for managing chronic prostate inflammation and cancer. This review proposes a multi-omics and bioinformatics-driven framework for developing TIM-3-centered diagnostic and therapeutic strategies.